Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 2.8%

Shares of Centessa Pharmaceuticals Limited (NASDAQ:CNTA) dropped 2.8% during mid-day trading on Wednesday . The stock traded as low as $24.57 and last traded at $24.57. Approximately 3,616 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 280,007 shares. The stock had previously closed at $25.27.

CNTA has been the topic of several research analyst reports. Morgan Stanley initiated coverage on Centessa Pharmaceuticals in a report on Tuesday. They issued an “overweight” rating and a $37.00 price objective on the stock. The Goldman Sachs Group initiated coverage on Centessa Pharmaceuticals in a report on Tuesday. They issued a “buy” rating and a $42.00 price objective on the stock. Finally, Jefferies Financial Group initiated coverage on Centessa Pharmaceuticals in a report on Tuesday. They set a “buy” rating and a $35.00 target price on the stock.

Centessa Pharmaceuticals Company Profile (NASDAQ:CNTA)

Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency.

Featured Article: How to calculate compound interest

Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.